A Call to Accountability: Reporting Outcomes in Vascularized Composite Allotransplantation

James L. Benedict, MDiv, STM, DMin, PhD*
Nicholas L. Robbins, DO†‡
Bruce Kaplan, MD, PhD§
Warren C. Breidenbach, MD†

Summary: Because nearly all the vascularized composite allotransplants performed in the United States have been proposed and carried out as research, the ethical duty to report outcomes pertains. This duty is set forth in several international statements, including the World Health Organization’s Statement on Public Disclosure of Clinical Trial Results, the 2013 Helsinki Declaration, and the Singapore Statement on Research Integrity. These international statements call for the reporting of negative and inconclusive outcomes as well as positive outcomes, and for the reporting of data from previously unreported past research. In 2014, the Organ Procurement and Transplant Network vascularized composite allotransplant committee proposed mandatory data collection and submission requirements for transplants, but only for those which took place in September 2015 or later. Reporting of data for the allotransplants which took place before September 2015 was regarded as optional, even though the pre-September 2015 transplants represent the majority of vascularized composite allotransplants in the United States and all the long-term outcome data. We encourage the American Society of Reconstructive Transplantation and the Organ Procurement and Transplant Network committee to embrace the international ethical standards and to hold all vascularized composite allotransplant programs in the United States accountable for reporting data on outcomes of pre-September 2015 transplants. (Plast Reconstr Surg Glob Open 2019;7:e2266; doi: 10.1097/GOX.0000000000002266; Published online 14 June 2019.)

INTRODUCTION

In 1964, as kidney transplantation using immunosuppression was just beginning, an attempt was made to transplant a hand and forearm. After this initial attempt failed due to rejection, interest in what has come to be known as vascularized composite allotransplantation (VCA) evaporated.6 Only after the development of more advanced immunosuppression did substantial work begin with research in nonhuman primates. Several attempts were made to perform VCA on nonhuman primates in the 1980s, but all failed within 6–12 months.6–9 The first modern VCA attempted in humans was attempted by Dr. Hoffman and his team in 1996, a knee transplant that survived for more than 1 year. The German team carried out 6 knee transplants over a 10-year period. Although all were lost within 56 months, graft survival of one significantly exceeded the graft survival of the first French transplant.10,11 In 1999, an American team in Louisville, Kentucky carried out what turned out to be the first upper extremity transplant with a long-term survival.11,12 Since that first attempt in the modern era, upper extremity transplantation has been performed on more than 75 patients worldwide.13,14 In addition, more than 40 patients have received a partial or full-face transplant.15 Others have received lower extremity, penis, larynx, abdominal wall, and uterus transplants.16–20 Although there have been some excellent outcomes in VCA, outcomes for the field as a whole remain mixed. Significant challenges remain if the field is to become established as a widely recognized and accepted form of treatment for large numbers of patients.

One recognized challenge in the field is a lack of routine data sharing.21–25 Although the Organ Procurement and Transplant Network (OPTN) VCA Committee provided a partial remedy to this problem with its requirement for data collection and submission for transplants...
from September 2015 forward, this remedy falls far short of international ethical standards for reporting the outcomes of research and deprives those in the field, potential patients, and the public of critical information. In the absence of this information, it is difficult to argue convincingly that the knowledge base, skills, and systems are in place to consistently produce good to excellent outcomes and that the field thus deserves the trust of patients and third-party payers.

**INTERNATIONAL RESEARCH REPORTING STANDARDS**

Concern over the failure to report outcome data of research has led to the creation of several statements by various international groups and funders of clinical research. Among these, the 2013 Helsinki Declaration, the 2017 statement of the World Health Organization (WHO), and the 2010 Singapore Statement of the World Conference on Research Integrity are the most prominent. In each of these, the ethical duty to report outcome data is emphasized.

The World Conferences on Research Integrity began in 2007 as an attempt to prevent misconduct and promote integrity across a wide range of research fields. The initial meeting was in Lisbon, Portugal, followed by meetings in Singapore (2010), Montreal (2013), Rio de Janeiro (2015), and Amsterdam (2017). It is noteworthy that an insistence on the importance of data reporting was a major feature of their very first group statement, the Singapore Statement on Research Integrity. Specifically, the statement calls on researchers to “report findings and interpretations fully and objectively . . . as soon as they have had the opportunity to establish priority and ownership claims.”

The World Medical Association, founded in 1947, has come to include thousands of physicians from over 100 countries. The Association’s focus is on medical ethics, human rights, and public health. In 1964, the Association published a statement on the ethics of human experimentation which was called the Declaration of Helsinki. Revisions of the Declaration have taken place periodically since, with the most recent in 2013. In the 2013 revision, a section titled “Research Registration and Publication and Dissemination of Results” was added. In that section, it is claimed:

Researchers have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports ... Negative and inconclusive as well as positive results must be published or otherwise made publicly available.

Inspired in part by the 2013 Helsinki Declaration, the WHO published its own “Statement on Public Disclosure of Clinical Trial Results” in 2017. In addition to the duties set forth in the Helsinki Declaration, the WHO Statement insists, “There is an ethical imperative to report the results of all clinical trials, including those of unreported trials conducted in the past.” Furthermore, the statement recommends that the failure to report results should be taken into account when funding future research is considered.

**THE ETHICAL FOUNDATION FOR REPORTING RESEARCH OUTCOMES**

Underlying the various formal statements are several substantive ethical arguments. Some of these arguments appear in the texts of the statements themselves, although only briefly. More substantive discussion of the ethical reasoning involved appears elsewhere. The ethical “rationale” for the WHO Statement is set out in an essay by Moorthy et al. From a primarily consequentialist perspective, they argue that not reporting results can create inefficiency, increase cost, and impede good decision-making. Similar consequentialist arguments appear in articles by De Hert and Samama, Shah and Batzer, and Bauchner et al.

Others offer ethical arguments for reporting outcomes grounded in rights and duties than in consequences. Hassoun focuses on the right to truly informed consent and the fundamental human right to reasonable protection from harm. She argues that when adverse results are not reported, the right of others to reasonable protection from harm is violated. Nicholls et al. set forth an argument based on the principles of fairness and reciprocity. They also assert a duty to society, grounded in “the ‘social license’ of research.” Bauchner et al., while leading with a consequentialist justification, also speak of a duty to research subjects who have put themselves at risk at least in part to generate knowledge that will benefit others.

Perhaps, the most thorough and readable argument for an ethical responsibility to report the outcome data of research comes from Iain Brassington. Brassington offers 4 reasons for why nonpublication of outcome data matters. First, he argues that it violates “the ‘ethos’ of scientific research.” According to Brassington, as progress in science depends on “replication and falsifiability,” and these are “undermined when some outcomes remain unpublished,” the failure to share outcome data “corrodes the nature of the scientific endeavor.”

Second, Brassington argues that nonpublication can lead to clinicians and patients making decisions “based on skewed information”. Clinicians might cause unintended and avoidable harm to patients, and patients are deprived of the ability to exercise genuine autonomy. Third, Brassington notes failure to share outcomes can lead to the waste of resources, as others pursue research that has already taken place. It can also waste resources that are used to provide treatments which have been shown (by the research data that was not shared) to be ineffective or even harmful. The fourth reason Brassington offers for an ethical obligation to share outcome data of research is similar to that offered by Bauchner et al and focuses on respect for research participants and their special contributions to the development of knowledge in the field of research. Participants in research may expect to contribute to knowledge acquisition which could be of benefit to others. Indeed, for some, this expectation may tip the balance in favor of participation in the research. When outcome data are not shared, the trust of research participants is betrayed and they are denied the opportunity to contribute to the common good.
RAISING THE STANDARDS FOR REPORTING VCA OUTCOMES

The international standards for reporting the outcome data of research on human subjects, including unreported research from the past, are quite robust. So, too, are the ethical arguments in support of such standards. Nonetheless, the current standard of the OPTN/United Network for Organ Sharing (UNOS) VCA Committee is less stringent and the actual practice of reporting data has not met the less stringent standard.\textsuperscript{24} Especially, concerning is the gent and the actual practice of reporting data has not met for Organ Sharing (UNOS) VCA Committee is less stringent.39 An important step toward earning trust with regard to traditional life-saving organ transplantation through efforts to be equitable, transparent, and inclusive.

Because of the great value of this data to practitioners, current patients, prospective patients, and potential third-party payers, the OPTN/UNOS VCA Committee and the American Society for Reconstructive Transplantation should align themselves with the WHO, the World Medical Association, and the World Conferences on Research Integrity by requiring all VCA teams in the United States to submit outcome data for transplants that took place between 1999 and September 2015 and continue to report on the condition of patients and grafts as these evolve. The requirement we have in mind is not a legal one, as neither the OPTN/UNOS VCA Committee nor the American Society for Reconstructive Transplantation (ASRT) is able to make laws. Rather, the requirement we have in mind is scientifically and medically ethical and can be expressed as organizational policy, with stated consequences. Programs that fail to comply with this requirement within a reasonable time frame should be publicly identified and perhaps otherwise sanctioned.

It is widely recognized that trust and transparency are critical to the success of the transplantation system in the United States.56–58 OPTN/UNOS has earned trust with regard to traditional life-saving organ transplantation through efforts to be equitable, transparent, and inclusive.\textsuperscript{59} An important step toward earning trust with regard to VCA will be for OPTN/UNOS to promote transparency by insisting that programs which wish to continue performing VCAs report their data from all past VCAs. The ASRTs stated goal of promoting “high standards in clinical care, science and ... ethical practice”\textsuperscript{40} implies support for strengthening the standard for outcome data reporting. The field of VCA was recently described in a leading journal as “maturing.”\textsuperscript{41} While progress is being made, the field cannot be described as “mature” from an ethical perspective until it holds programs and practitioners more accountable and to a higher standard.

James L. Benedict, MDio, STM, DMin, PhD
Center for Healthcare Ethics, Duquesne University,
Pittsburgh, Pa. P.O. Box 48
New Windsor, MD 21776
Benedictcj@duq.edu

REFERENCES

1. World Health Organization International Clinical Trials Platform (SUI). Joint statement on public disclosure of results from clinical trials [internet]. Geneva, Switzerland: World Health Organization; 2018. Available at: https://www.who.int/ictrp/results/jointstatement/en/. Accessed October 19, 2018.

2. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4.

3. World Conferences on Research Integrity. Singapore statement [internet]. World Conferences on Research Integrity; 2010. Available at https://wcrif.org/guidance/singapore-statement. Accessed October 19, 2018.

4. Organ Procurement and Transplantation Network (US). OPTN VCA data collection policy [internet]. Richmond, Va.: OPTN; 2015. Available at https://optn.transplant.hrsa.gov/news/vca-data-collection/. Accessed October 20, 2018

5. Gilbert Fernandez JJ, Febres-Cordero RG, Simpson RL. The untold story of the first hand transplant: dedicated to the memory of one of the great minds of the Ecuadorian medical community and the world. J Reconsr Microsurg. 2019;35:165–167.

6. Gold ME, Randzio J, Kniah H, et al. Transplantation of vascularized composite mandibular allografts in young cynomolgus monkeys. Ann Plast Surg. 1991;26:122–132.

7. Stevens HP, Hovius SE, Vuzevski VD, et al. Immunological aspects of allogeneic partial hand transplantation in the rhesus monkey. Transplant Proc. 1990;22:2006–2008.

8. Hovius SE, Stevens HP, van Nierop PW, et al. Allogeneic transplantation of the radial side of the hand in the rhesus monkey: I. Technical aspects. Plast Reconstr Surg. 1992;89:700–709.

9. Daniel RK, Egerszegi EP, Samulack DD, et al. Tissue transplants in primates for upper extremity reconstruction: a preliminary report. J Hand Surg Am. 1986;11:1–8.

10. Diefenbeck M, Nerlich A, Schneeberger S, et al. Allograft vasculopathy after allogeneic vascularized knee transplantation. Transpl Int. 2011;24:e1–5.

11. Jones JW, Gruber SA, Barker JH, et al. Successful hand transplantation. One-year follow-up. Louisville Hand Transplant Team. N Engl J Med. 2000;343:468–473.

12. ABC News (US). US hand transplant patient doing fine [Internet]. New York, N.Y.: ABC News; 2018. Available at https://abcnews.go.com/Health/story?id=118039&page=1. Accessed November 6, 2018.

13. Alolabi N, Augustine H, Thoma A. Hand transplantation: current challenges and future prospects. Transplant Res Risk Manage. 2017;9:23–29.

14. Breidenbach WC, Meister EA, Becker GW, et al. A statistical comparative assessment of face and hand transplantation outcomes to determine whether either meets the standard of care threshold. Plast Reconstr Surg. 2016;137:214e–222e.

15. Kollar B, Tasigioros S, Dorante MI, et al. Innovations in reconstructive microsurgery: reconstructive transplantation. J Surg Oncol. 2018;118:800–806.

16. Cavadas PC, Thione A, Carballeira A, et al. Bilateral transfemoral lower extremity transplantation: result at 1 year. Am J Transplant. 2013;13:1543–1549.

17. Sopko NA, Tuffaha SH, Lough D, et al. Penile allotransplantation for complex genitourinary reconstruction. J Urol. 2017;198:274–280.

18. Krishnan G, Du C, Fishman JM, et al. The current status of human laryngeal transplantation in 2017: a state of the field review. Laryngoscope. 2017;127:1861–1868.

19. Light D, Kundu N, Djojan R, et al. Total abdominal wall transplantation: an anatomical study and classification system. Plast Reconstr Surg. 2017;139:1466–1473.
20. Brännström M, Dahm Kähler P, Greite R, et al. Uterus transplantation: a rapidly expanding field. *Transplantation*. 2018;102:569–577.

21. Benedict J, Magill G. Ethics and the future of vascularized composite allotransplantation. *Curr Transplant Rep*. 2018;5:334–338.

22. Caplan AL, Parent B, Kahn J, et al. Emerging ethical challenges raised by the evolution of vascularized composite allotransplantation [published ahead on print October 8, 2018]. *Transplantation*. doi:10.1097/TP.0000000000002478.

23. Kaufman CL, Ouseph R, Marvin MR, et al. Monitoring and long-term outcomes in vascularized composite allotransplantation. *Curr Opin Organ Transplant*. 2013;18:652–658.

24. Cherikh WS, Cendales LC, Wholley CL, et al. Vascularized composite allotransplantation in the United States: a descriptive analysis of the Organ Procurement and Transplantation Network Data. *Am J Transplant*. 2019;19:865–875.

25. OPTN/UNOS (US). Vascularized composite allotransplantation (VCA) Committee minutes April 6, 2018 [internet]. Richmond, Va.: OPTN; 2018. Available at https://optn.transplant.hrsa.gov/media/2668/20180406_vca_meetingsummary.pdf. Accessed October 22, 2018.

26. World Conferences on Research Integrity. Early history of the world conferences on research integrity [internet]. 2018. Available at https://wcrif.org/conferences/early-history. Accessed October 15, 2018.

27. World Medical Association (FR). What we do [Internet]. 2018. Available at https://www.wma.net/what-we-do/. Accessed October 15, 2018.

28. World Medical Association (FR). 2013 Revision of the Declaration of Helsinki [Internet]. France: Ferney-Voltaire. 2013. Available at https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed October 22, 2018.

29. Moorthy VS, Karam G, Vannice KS, et al. Rationale for WHO’s new position calling for prompt reporting and public disclosure of interventional clinical trial results. *PLoS Med*. 2015;12:e1001819.

30. De Hert S, Samama CM. Open access to research data: the two sides of the coin. *Eur J Anaesthesiol*. 2017;34:1–3.

31. Shah KR, Batzer FR. Improving subject recruitment by maintaining truly informed consent: a practical benefit of disclosing adverse clinical trial results. *Am J Bioeth*. 2009;9:36–37.

32. Bauchner H, Golub RM, Fontanarosa PB. Data sharing: an ethical and scientific imperative. *JAMA*. 2016;315:1237–1239.

33. Hassoun N. The duty to disclose (even more) adverse clinical trial results. *Am J Bioeth*. 2009;9:33–34.

34. Nicholls SG, Langan SM, Benchimol EI, et al. Reporting transparency: making the ethical mandate explicit. *BMC Med*. 2016;14:44.

35. Brassington I. The ethics of reporting all the results of clinical trials. *Br Med Bull*. 2017;121:19–29.

36. Fox MD. Stewards of public trust: responsible transplantation. *Am J Bioeth*. 2003;3:v–vii.

37. Pondrom S. Trust is everything. *Am J Transplant*. 2013;13:1115–1116.

38. Morgan SE, Harrison TR, Afifi WA, et al. In their own words: the reasons why people will (not) sign an organ donor card. *Health Commun*. 2008;23:23–33.

39. OPTN/UNOS (US). UNOS strategic goals [internet]. Richmond, Va., 2018. Available at https://unos.org/about/strategic-goals/. United Network for Organ Sharing, Richmond, VA. Accessed October 22, 2018.

40. American Society for Reconstructive Transplantation (US). ASRT mission [internet]. Chicago, Ill. Available at http://www2.asrt.com/aboutus/index.html. Accessed October 22, 2018. American Society for Reconstructive Transplantation, Chicago, IL.

41. Brandacher G. Vascularized composite allotransplantation: a field is maturing. *Curr Opin Organ Transplant*. 2018;23:559–560.